MRSN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Mersana Therapeutics, Inc. is Fair to Shareholders

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the proposed sale of Mersana Therapeutics, Inc. to Day One Biopharmaceuticals, Inc. for Mersana shareholders, focusing on whether the transaction terms are equitable and if the board fulfilled its fiduciary duties [1][3]. Transaction Details - Mersana shareholders are set to receive $25.00 per share in cash, along with one non-tradable contingent value right (CVR) per share, which could yield additional milestone payments of up to $30.25 per CVR, totaling a potential maximum of $55.25 per share [1]. Legal Investigation - The investigation aims to determine if Mersana and its board violated federal securities laws or breached fiduciary duties by not securing the best possible consideration for shareholders, assessing whether Day One is underpaying, and failing to disclose all material information necessary for shareholders to evaluate the merger [3]. Potential Actions - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other forms of relief related to the proposed transaction, operating on a contingent fee basis [4].